Statin Landmark Trials Across the Spectrum of Risk:Secondary CV Prevention

Slide lecture program (17 slides): View & Download

1. TNT: Study Design Treating to New Targets
2. TNT Primary Efficacy Outcome Measure:Major Cardiovascular Events
3. TNT: Primary and Secondary Efficacy Outcomes
4. TNT: Time to First Fatal or Nonfatal Stroke
5. TNT: Safety Profile
6. IDEAL (Incremental Decrease in EndPoints Through Aggressive Lipid Lowering): Study Design
7. IDEAL: Primary and Secondary End Points
8. Effects of Atorvastatin 80 mg/d vs Simvastatin 20 to 40 mg/d on Any CV Event
9. MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering): Study Design
10. MIRACL: Primary Efficacy Measure—Time to First Event
11. MIRACL: Stroke
12. PROVE IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction) 22: Study Design
13. PROVE IT: Primary End Point (All-Cause Death or Major CV Events in All Randomized Subjects)
14. PROVE IT-TIMI 22: Intensive Therapy With Statins in Patients With ACS: Early and Long-term Benefits
15. Safety of Atorvastatin 80 mg in Clinical Trials
16. Overview of Adverse Events forAtorvastatin 10 mg and 80 mg and Placebo
17. TNT: Changes in LDL-C by Treatment
18. PROVE IT: Reductions in Major Cardiac End Point
19. Effect of Intensive Statin Therapy on Clinical Outcomes
20. Long-term Statin Treatment in IDEAL Maintained Benefit Over 5 Years
21. MIRACL: Secondary End Points
22. Association of Dyslipidemia and myocardial Infarction Risk: INTERHEART
23. ASCOT CRP Analysis

Click on slides to preview

Download slides below

634918751162798750-Download slides CV risk and lipid management. section 4 (PPTX 579KB)

Statin Landmark Trials Across the Spectrum of Risk	TNT: Study Design Treating to New Targets
TNT Primary Efficacy Outcome Measure	TNT: Primary and SecondaryEfficacy Outcomes
TNT: Time to First Fatal or Nonfatal Stroke	TNT: Safety Profile
IDEAL Study Design	IDEAL: Primary and Secondary End Points
Effects of Atorvastatin 80 mg/d vs Simvastatin	MIRACL: Study Design
MIRACL: Primary Efficacy Measure	MIRACL: Stroke
PROVE IT-TIMI 22: Study Design	PROVE IT: Primary End Point
PROVE IT-TIMI 22: Intensive Therapy	Safety of Atorvastatin 80 mg in Clinical Trials
Overview of Adverse Events forAtorvastatin	TNT: Changes in LDL-C by Treatment Group
PROVE IT: Reductions in Major Cardiac End Points	Effect of Intensive Statin Therapy on Clinical Outcomes
Long-term Statin Treatment in IDEAL	MIRACL: Secondary End Points
Association of Dyslipidemia andMI Risk: INTERHEART	ASCOT CRP Analysis